Targeting epigenetic regulators for cancer therapy

Annals of the New York Academy of Sciences

Volumn 1309, Issue 1, 2014, Pages 30-36

  Wee, Susan ^a   Dhanak, Dash ^b   Li, Haitao ^c   Armstrong, Scott A ^d   Copeland, Robert A ^e   Sims, Robert ^f   Baylin, Stephen B ^g   Liu, Xiaole Shirley ^h   Schweizer, Liang ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b API Large Molecule Pharmaceutical Development and Manufacturing Sciences   (United States)

^c TSINGHUA UNIVERSITY   (China)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e EPIZYME INC   (United States)

^f Department of Lead Discovery   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; DOT1L; Drug discovery; Epigenetic regulators; EZH; MLL

Indexed keywords

HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE DOT 1 L; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE TARGETING; HUMAN; PROTEIN PROCESSING; TRANSLATIONAL RESEARCH;

CANCER THERAPY; DOT1L; DRUG DISCOVERY; EPIGENETIC REGULATORS; EZH; MLL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84894493778     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12356     Document Type: Article

References (27)

1. Martin-Subero, J.I., C. Lopez-Otin & E. Campo. 2013. Genetic and epigenetic basis of chronic lymphocytic leukemia. Curr. Opin. Hematol. 20: 362-368.
2. Esteller, M., L. Catasus, X. Matias-Guiu, et al. 1999. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am. J. Pathol. 155: 1767-1772.
3. Schuebel, K.E., W. Chen, L. Cope, et al. 2007. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 3: 1709-1723.
4. Chen, S.S., A. Raval, A.J. Johnson, et al. 2009. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 106: 13433-13438.
5. Geutjes, E.J., P.K. Bajpe & R. Bernards. 2012. Targeting the epigenome for treatment of cancer. Oncogene 31: 3827-3844.
6. Jakopovic, M. et al. 2013. Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front. Oncol. 3: 261.
7. Jenuwein, T. & C.D. Allis. 2001. Translating the histone code. Science 293: 1074-1080.
8. Taverna, S.D. et al. 2007. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol. 14: 1025-1040.
9. Ruthenburg, A.J. et al. 2007. Multivalent engagement of chromatin modifications by linked binding modules. Nat. Rev. Mol. Cell Biol. 8: 983-994.
10. Iwase, S. et al. 2011. ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome. Nat. Struct. Mol. Biol. 18: 769-776.
11. Bernt, K.M. & S.A. Armstrong. 2011. Targeting epigenetic programs in MLL-rearranged leukemias. Hematol. Am. Soc. Hematol. Educ. Program. 2011: 354-360.
12. Bernt, K.M. et al. 2011. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66-78.
13. Neff, T. et al. 2012. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc. Natl. Acad. Sci. USA 109: 5028-5033.
14. Daigle, S.R. et al. 2013. Potent inhibition of DOT1L as a treatment for MLL-fusion leukemia. Blood 122: 1017-1025.
15. Knutson, S.K. et al. 2013. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 110: 7922-7927.
16. Daigle, S.R. et al. 2011. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20: 53-65.
17. Deshpande, A.J., J. Bradner & S.A. Armstrong. 2012. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 33: 563-570.
18. Copeland, R.A., M.P. Moyer & V.M. Richon. 2013. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 32: 939-946.
19. Knutson, S.K. et al. 2012. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8: 890-896.
20. Lund, K., P.D. Adams & M. Copland. 2014. EZH2 in normal and malignant hematopoiesis. Leukemia. 28: 44-49.
21. Mertz, J.A. et al. 2011. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 108: 16669-16674.
22. Delmore, J.E. et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
23. Baylin, S.B. & P.A. Jones. 2011. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11: 726-734.
24. Berman, B.P. et al. 2012. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44: 40-46.
25. Tsai, H.C. et al. 2012. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446.
26. Li, Y. & H. Li. 2012. Many keys to push: diversifying the 'readership' of plant homeodomain fingers. Acta Biochim. Biophys. Sin (Shanghai) 44: 28-39.
27. Xu, K. et al. 2012. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338: 1465-1469.